PMC isochem

Executive Summary

PMC Isochem is a French Contract Development and Manufacturing Organization (CDMO) established in 1990 and headquartered in Vert-le-Petit. The company specializes in the custom development and manufacturing of small molecule intermediates, active pharmaceutical ingredients (APIs), excipients, and polymers for drug delivery solutions. Operating under current Good Manufacturing Practice (cGMP) standards, PMC Isochem provides comprehensive services from early-stage development to commercial-scale production. Recently, the company has expanded its capabilities by offering Contract Research Organization (CRO) services focused on analytical development and nanoformulation, positioning itself as a versatile partner for pharmaceutical companies seeking integrated drug development solutions. With over three decades of experience, PMC Isochem serves a diverse client base ranging from biotech startups to established pharmaceutical firms. The company’s expertise in nanoformulation and polymer-based drug delivery addresses the growing demand for advanced delivery systems. While financial details are not publicly disclosed, the company’s strategic expansion into CRO activities signals a commitment to capturing higher-value segments of the pharmaceutical value chain. As the CDMO market continues to grow, PMC Isochem is well-positioned to benefit from increasing outsourcing trends in Europe and globally. However, competition from larger CDMOs remains a challenge, and the company’s ability to differentiate through specialized technologies will be key to its success.

Upcoming Catalysts (preview)

• Q3 2026Launch of nanoformulation CRO service line70% success
• Q4 2026Major manufacturing contract with top-20 pharma50% success
• Q2 2027Completion of capacity expansion at Vert-le-Petit facility65% success